|
|||||
|
|
| 伊立替康联合铂类药物治疗广泛期SCLC的研究进展 | |
| 引用本文： | 朱晓锋,朱洁梅. 伊立替康联合铂类药物治疗广泛期SCLC的研究进展[J]. 实用肿瘤学杂志, 2015, 29(1): 69-72. DOI: 10.11904/j.issn.1002-3070.2015.01.015 |
| 作者姓名： | 朱晓锋 朱洁梅 |
| 作者单位： | 常熟市第一人民医院中医科(常熟 215500) |
| 摘 要： | 小细胞肺癌(Small cell lung cancer,SCLC)在肺癌中约占10%~15%,是一种恶性程度较高的肿瘤,具有进展快且转移早的特点,联合化疗是广泛期SCLC主要的治疗方法。依托泊苷(Etoposide,VP-16)联合顺铂(Cisplatin,DDP)的方案(简称EP方案)是治疗广泛期小细胞肺癌(Extensive disease small cell lung cancer,ED-SCLC)的标准方案,这些年来并未取得突破性的治疗进展。伊立替康联合铂类抗肿瘤药物的方案在治疗ED-SCLC方面显示出有效性和安全性,本文就伊立替康联合铂类药物治疗ED-SCLC的现状做一简要综述。 |
| 收稿时间： | 2014-08-24 |
Combined chemotherapy of irinotecan/platinum in extensive disease SCLC |
|
| ZHU Xiaofeng,ZHU Jiemei. Combined chemotherapy of irinotecan/platinum in extensive disease SCLC[J]. Journal of Practical Oncology, 2015, 29(1): 69-72. DOI: 10.11904/j.issn.1002-3070.2015.01.015 | |
| Authors: | ZHU Xiaofeng ZHU Jiemei |
| Affiliation: | Department of TCM,Changshu NO.1 People′s Hospital,Changshu 215500,China |
| Abstract: | Small cell lung cancer(SCLC),characterized with rapid growth and early metastasis,accounts for about 15~20 percent of all kinds of lung cancer.Patients with extensive disease of SCLC should be treated with combined chemotherapy.The standard treatment for extensive SCLC is etoposide combined with platinum,shortly for EP,with no breakthrough progress in the last decades.This paper briefly reviews the combination of irinotecan/platinum that showed effectiveness and safety in the treatment of extensive SCLC. |
| Keywords: | |
| 本文献已被 万方数据 等数据库收录！ | |
| 点击此处可从《实用肿瘤学杂志》浏览原始摘要信息 | |
| 点击此处可从《实用肿瘤学杂志》下载免费的PDF全文 | |